Reviewer’s report

Title: CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.

Version: 1 Date: 18 Aug 2017

Reviewer: Kylie Louise Gorringe

Reviewer's report:

I appreciate the efforts made by the authors to address my concerns, my remaining points are minor.

Methods: say KRAS exon 15, but primers are for exon 2, please change methods to exon 2.

Methods: typo "1,385 genes"

Results - in the section describing the mutation screening, please give the exact KRAS mutation for both the cDNA and protein change using HGVS nomenclature (http://varnomen.hgvs.org/). This paragraph also needs revising for grammar.

In Table 2 what do the x3, x1, x29 etc mean? Especially the ones that are x29-30 for example on chr2, chr12. Also "hmz"

In my earlier review I referred to the black and grey lines to Fig3, when I meant to refer to Fig 4 (the CN profiles). I apologise for this mistake, which no doubt led to some confusion! The supplementary tables now provide information on the cnLOH regions, but perhaps for what is now Figure 5 just add to the legend what the differences between the grey and black dots/lines are - one presumably corresponds to allele differences, while the other is the CN state?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal